Gavin Xia
Chief Executive Officer chez Shanghai Alebund Pharmaceutical Technology Co., Ltd.
Profil
Gavin Xia is the founder of Shanghai Alebund Pharmaceutical Technology Co., Ltd.
He is currently working as a Venture Partner at LAV Management Co., Ltd.
Previously, he worked as a Non-Executive Director at Abbisko Therapeutics Co., Ltd.
and as a Director at Beijing Jiakesi New Drug Development Co. Ltd.
He also served as a Non-Executive Director at Abbisko Cayman Ltd.
from 2016 to 2023 and as a Director at Shanghai Kun Yuan Biotechnology Co. Ltd.
from 2016 to 2021.
Dr. Xia completed his undergraduate degree from Peking University in 2001 and received his doctorate degree from The University of Chicago in 2007.
Postes actifs de Gavin Xia
| Sociétés | Poste | Début |
|---|---|---|
LAV Management Co., Ltd.
 LAV Management Co., Ltd. Investment ManagersFinance LAV Management Co., Ltd. (LAV) is a venture capital subsidiary of Eli Lilly & Co. founded in 2008. The firm is headquartered in Shanghai, China with branches located in Central, Hong Kong and California, United States. | Private Equity Investor | - |
Shanghai Alebund Pharmaceutical Technology Co., Ltd.
 Shanghai Alebund Pharmaceutical Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Alebund Pharmaceutical Technology Co., Ltd. is a clinical stage biopharmaceutical company based in Shanghai, China. The Chinese company focuses on discovering and developing novel therapies for kidney diseases. | Chief Executive Officer | - |
Anciens postes connus de Gavin Xia
| Sociétés | Poste | Fin |
|---|---|---|
| ABBISKO CAYMAN LIMITED | Director/Board Member | 19/06/2023 |
| Shanghai Kun Yuan Biotechnology Co. Ltd. | Director/Board Member | 01/02/2021 |
Beijing Jiakesi New Drug Development Co. Ltd.
 Beijing Jiakesi New Drug Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Jiakesi New Drug Development Co. Ltd. develops and sells drugs. The company was founded by Yinxiang Wang on July 17, 2015 and is headquartered in Beijing, China. | Director/Board Member | - |
Abbisko Therapeutics Co., Ltd.
 Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China. | Director/Board Member | - |
Formation de Gavin Xia
| Peking University | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ABBISKO CAYMAN LIMITED | Health Technology |
| Entreprise privées | 5 |
|---|---|
LAV Management Co., Ltd.
LAV Management Co., Ltd. Investment ManagersFinance LAV Management Co., Ltd. (LAV) is a venture capital subsidiary of Eli Lilly & Co. founded in 2008. The firm is headquartered in Shanghai, China with branches located in Central, Hong Kong and California, United States. | Finance |
Abbisko Therapeutics Co., Ltd.
Abbisko Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China. | Health Technology |
Beijing Jiakesi New Drug Development Co. Ltd.
Beijing Jiakesi New Drug Development Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Jiakesi New Drug Development Co. Ltd. develops and sells drugs. The company was founded by Yinxiang Wang on July 17, 2015 and is headquartered in Beijing, China. | Health Technology |
Shanghai Alebund Pharmaceutical Technology Co., Ltd.
Shanghai Alebund Pharmaceutical Technology Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Alebund Pharmaceutical Technology Co., Ltd. is a clinical stage biopharmaceutical company based in Shanghai, China. The Chinese company focuses on discovering and developing novel therapies for kidney diseases. | Health Technology |
| Shanghai Kun Yuan Biotechnology Co. Ltd. |
